# Trump Turns Over New Leaf in GOP Drug Policy with Marijuana, Psychedelics Orders > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/trump-gop-drug-policy-marijuana-psychedelics-update/ > **Published:** 2026-04-25T17:03:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:10:40-04:00 > **Clinical Summary:** Explore the impact of Trump GOP drug policy marijuana psychedelics orders on federal regulation and patient access to cannabis medicine. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyFederal RegulationClinical AccessResearch[Patient Care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) Why This Matters Federal policy changes directly impact patient access to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) capabilities. Shifts in regulatory approach can accelerate or constrain the evidence base clinicians need to make informed treatment decisions. Clinical Summary Political developments in drug policy signal potential changes to federal scheduling, research funding, and regulatory frameworks governing cannabis and psychedelics. Such policy shifts historically influence state-level implementation, insurance coverage considerations, and the pace of [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). The actual clinical impact depends on specific regulatory changes rather than political positioning. Dr. Caplan’s Take “I focus on what policies actually enable: better research, clearer dosing standards, and improved patient access to quality-controlled products. Political winds change, but patients need [evidence-based medicine](https://cedclinic.com/digital-health-expertise-modern-challenge/) regardless of the administration.” Clinical Perspective 🧠 Clinicians should monitor concrete regulatory changes rather than political rhetoric. Watch for updates to DEA scheduling, FDA guidance on [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), and changes to federal research funding. [Patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions should remain grounded in available evidence, not anticipated policy shifts. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20turns%20over%20new%20leaf%20in%20GOP%20drug%20policy%20with%20marijuana%2C%20psychedelics%20orders%20%E2%80%93%20The%20Hill%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Ftrump-turns-over-new-leaf-in-gop-drug-policy-with-marijuana-psychedelics-orders%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Ftrump-turns-over-new-leaf-in-gop-drug-policy-with-marijuana-psychedelics-orders%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20turns%20over%20new%20leaf%20in%20GOP%20drug%20policy%20with%20marijuana%2C%20psychedelics%20orders%20%E2%80%93%20The%20Hill%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Ftrump-turns-over-new-leaf-in-gop-drug-policy-with-marijuana-psychedelics-orders%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://thehill.com/policy/healthcare/5848366-gop-shift-trump-drug-reform/](https://thehill.com/policy/healthcare/5848366-gop-shift-trump-drug-reform/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What type of cannabis-related topics does this article cover?](#What_type_of_cannabis-related_topics_does_this_article_cover) - [Who is the source of this cannabis news?](#Who_is_the_source_of_this_cannabis_news) - [Why is this considered “emerging” information?](#Why_is_this_considered_8220emerging8221_information) - [What should healthcare professionals do with this information?](#What_should_healthcare_professionals_do_with_this_information) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has received a CED Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This classification means the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What type of cannabis-related topics does this article cover? The article focuses on policy and federal regulation aspects of cannabis. It also addresses clinical access and research components related to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). #### Who is the source of this cannabis news? This cannabis news is published by CED Clinic. The information appears to be part of their ongoing coverage of cannabis-related developments in healthcare and policy. #### Why is this considered “emerging” information? The article is marked as “New” and classified under emerging findings or policy developments. This suggests the information represents recent changes or discoveries in cannabis regulation or clinical practice that warrant professional attention. #### What should healthcare professionals do with this information? Healthcare professionals should monitor this information closely given its “Notable Clinical Interest” rating. The content may impact clinical practice, patient access, or regulatory compliance in cannabis medicine. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump DOJ Deregulates Marijuana to the Dismay of Health Experts – The Washington Stand](https://cedclinic.com/trump-doj-deregulates-marijuana-federal-policy-impact/) An analysis of the Trump DOJ's deregulation of marijuana and its implications for health experts and patient care. [Read More](https://cedclinic.com/trump-doj-deregulates-marijuana-federal-policy-impact/) Trump admin institutes new marijuana rules – New York Post Coverage of the new marijuana rules introduced by the Trump administration and their regulatory impact. Explore Details [Trump Administration Moves to Reclassify Marijuana as Schedule III Drug | National News](https://cedclinic.com/trump-administration-cannabis-scheduling-changes/) Insight into the Trump administration's efforts to reclassify marijuana and the potential clinical and research effects. [Learn More](https://cedclinic.com/trump-administration-cannabis-scheduling-changes/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).